Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cholecystitis01:20

Cholecystitis

Cholecystitis is inflammation of the gallbladder, most commonly caused by obstruction of the cystic duct. This blockage prevents bile from draining, leading to gallbladder distension, inflammation, and potentially serious complications. This condition may present acutely or chronically and can happen with or without gallstones.EtiologyAbout 95% of cholecystitis cases are calculous, caused by gallstones blocking the cystic duct, leading to bile accumulation and inflammation of the gallbladder...
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Chronic Pancreatitis II: Pathophysiology01:21

Chronic Pancreatitis II: Pathophysiology

Chronic pancreatitis is a progressive and irreversible inflammation of the pancreas, most often caused by long-term alcohol abuse, but it can also be related to ductal obstruction, smoking, or genetic factors.Chronic pancreatitis occurs when the pancreas is repeatedly exposed to harmful agents like alcohol, smoking, ductal obstruction, or genetic predisposition. These factors lead to the release of toxic metabolites and inflammatory cytokines, sustaining chronic inflammation in the pancreatic...
Chronic Pancreatitis I: Introduction01:25

Chronic Pancreatitis I: Introduction

Chronic pancreatitis is a long-standing, relapsing inflammation of the pancreas, characterized by irreversible damage to the gland. It results in progressive destruction of the pancreatic parenchyma, fibrosis, and eventual loss of both exocrine and endocrine function. The disease may evolve gradually after multiple episodes of acute pancreatitis or develop independently.EtiologyChronic pancreatitis can arise from a variety of causes:Alcohol use is the leading cause, accounting for 70–80% of...
Chronic Pancreatitis I: Introduction01:24

Chronic Pancreatitis I: Introduction

The pancreas, an elongated and flat gland situated behind the stomach, serves a vital function in digesting food and managing blood sugar levels.
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute upper gastrointestinal bleeding: a population-based cohort study from Southern Iceland.

Scandinavian journal of gastroenterology·2026
Same author

Monoclonal gammopathy of undetermined significance is not associated with increased risk of skin cancer.

The British journal of dermatology·2026
Same author

HLA-B*44 Alleles and HLA-DQA1*03:01 as Genetic Risk Factors for Drug-Induced Liver Injury due to Fluoroquinolones.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

An update on drug-induced liver injury-What's new?

Journal of internal medicine·2026
Same author

Exploring the influence of sex on <i>idiosyncratic</i> DILI: impact on risk assessment.

Expert opinion on drug metabolism & toxicology·2026
Same author

Editorial: The Role of Liver Biopsy in ANA Positive Subjects.

Alimentary pharmacology & therapeutics·2026

Related Experiment Video

Updated: May 12, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

Drug-induced cholestasis.

Einar S Bjornsson1, Jon Gunnlaugur Jonasson

  • 1Division of Gastroenterology and Hepatology, The National University Hospital of Iceland, Hringbraut 101, Reykjavik, Iceland. einarsb@landspitali.is

Clinics in Liver Disease
|April 2, 2013
PubMed
Summary

Drug-induced liver injury (DILI) can cause cholestasis, a condition affecting bile flow. Diagnosis requires evaluating patient history, drug exposure, and liver function tests, as DILI can lead to severe liver damage.

Area of Science:

  • Hepatology
  • Clinical Pharmacology
  • Gastroenterology

Background:

  • Cholestasis, characterized by impaired bile flow, necessitates considering drug-induced liver injury (DILI) in differential diagnoses.
  • Biochemical cholestatic patterns are key indicators requiring thorough investigation.

Purpose of the Study:

  • To highlight the diagnostic considerations for drug-induced cholestasis.
  • To emphasize the importance of patient history and drug-induced hepatotoxicity in diagnosing DILI.

Main Methods:

  • Clinical evaluation based on patient's underlying condition and detailed drug history.
  • Assessment of serologic tests and radiological imaging in the context of clinical presentation.
  • Consideration of drug rechallenge results and documented hepatotoxicity.

More Related Videos

Creation of Reversible Cholestatic Rat Model
09:39

Creation of Reversible Cholestatic Rat Model

Published on: May 21, 2011

Related Experiment Videos

Last Updated: May 12, 2026

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

Creation of Reversible Cholestatic Rat Model
09:39

Creation of Reversible Cholestatic Rat Model

Published on: May 21, 2011

Main Results:

  • Most cases of cholestatic DILI are mild.
  • Rarely, ductopenia and cholestatic cirrhosis can develop.
  • Approximately 10% of patients with drug-induced cholestatic jaundice may progress to liver failure.

Conclusions:

  • Establishing a diagnosis of DILI requires a comprehensive approach integrating clinical context, drug history, and toxicological evidence.
  • While often mild, cholestatic DILI carries a risk of severe outcomes, including liver failure, underscoring the need for timely diagnosis and management.